Demographic details of the study cohorts
| AATD genotype | MM | MZ | ZZ | ZZ augmentation | P value |
| Total number | 23 | 22 | 21 | 6 | – |
| Healthy | 8 | 7 | 6 | 1 | – |
| Smoker | 5 | 8 | 0 | 0 | – |
| COPD | 10 | 7 | 15 | 5 | – |
| Age in years | 58±13 | 53±14 | 52±16 | 60±16 | 0.30 |
| Healthy | 54±18 | 53±12 | 34±13 | 33 | 0.07 |
| Smoker | 55±7 | 44±14 | – | – | 0.14 |
| COPD | 64±7 | 62±9 | 59±10 | 66±10 | 0.43 |
| Male | 13 (57%) | 14 (64%) | 6 (29%) | 4 (67%) | – |
| FEV1 | 86±20 | 87±24 | 83±31 | 54±26 | 0.04 |
| Healthy | 100±11 | 102±17 | 117±13 | 101 | 0.14 |
| Smoker | 99±8 | 96±11 | – | – | 0.81 |
| COPD | 66±15 | 64±25 | 68±23 | 45±14 | 0.19 |
| BMI | 29±8 | 27±5 | 25±5 | 26±2 | 0.59 |
Data are presented as number or mean±SD.
Comparisons made using analysis of variance except for the smoking cohorts where Mann-Whitney test was used.
AATD, alpha-1 antitrypsin deficiency; BMI, body mass index (kg/m2); COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s (% predicted).